Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers

Surgical Treatment of Breast Cancer in BRCA-Mutation Carriers.

Role of Breast Surgery in BRCA Mutation Carriers.

BRCA mutation carriers have a life-long breast cancer risk between 55 and 85% and a high risk of developing breast cancer at a very young age, depending on the type of mutation. The risk of developing contralateral breast cancer after a first breast cancer is elevated up to 65%, especially in case of BRCA1 mutation and young age at the first breast cancer. Since bilateral prophylactic mastectom...

Breast cancer in BRCA mutation carriers: breast-conserving therapy or bilateral mastectomy?

Use of systemic hormone therapy in BRCA mutation carriers.

As more women are being counseled and tested, clinicians increasingly encounter women with identified BRCA1 and BRCA2 gene mutations. Existing, albeit limited, data indicate that risks of breast cancer are not increased with use of systemic hormone therapy by menopausal BRCA mutation carriers with intact breasts. Young mutation carriers with or without intact breasts should not defer or avoid r...

Breast cancer following ovarian cancer in BRCA mutation carriers.

IMPORTANCE BRCA mutation carriers are at increased risk of developing breast cancer. However, the incidence of breast cancer after a diagnosis of epithelial ovarian cancer (EOC), one of the tubal/peritoneal cancers collectively referred to as pelvic serous carcinomas, is not well known. Optimal breast cancer surveillance and detection for these patients have also not been well characterized. ...